Sun Pharma Board has appointed Aalok Shanghvi as a whole-time director for a five-year term beginning June 1, 2023. Shanghvi, the son of Sun Pharma's founder-promoter and managing director Dilip Shanghvi, has been heading key functions, including emerging markets, global generic R&D, global generic business development, and active pharmaceutical ingredient since joining the firm in 2006. The board also approved Rolf Hoffmann's appointment as an independent director for the next five years. Hoffmann has extensive experience in managing worldwide markets and creating commercial opportunities, having previously worked as an executive at Eli Lilly and Amgen.